Basilea Pharmaceutica (0QNA) Stock Statistics & Valuation Metrics
Total Valuation
Basilea Pharmaceutica has a market cap or net worth of CHF 871.17M. The enterprise value is CHF 644.92M.
- Market Cap
- CHF 871.17M
- Enterprise Value
- CHF 644.92M
Share Statistics
Basilea Pharmaceutica has 13,442,679 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,442,679
- Owned by Insiders
- ―
- Owned by Institutions
- 14.76%
Financial Efficiency
Basilea Pharmaceutica’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 19.29%.
- Return on Equity (ROE)
- 0.31
- Return on Assets (ROA)
- 0.14
- Return on Invested Capital (ROIC)
- 19.29%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 1.16M
- Profits Per Employee
- 201.00K
- Employee Count
- 200
- Asset Turnover
- 0.82
- Inventory Turnover
- 1.82
Valuation Ratios
The current PE Ratio of Basilea Pharmaceutica is 16.62. Basilea Pharmaceutica’s PEG ratio is -1.37.
- PE Ratio
- 16.62
- PS Ratio
- 3.55
- PB Ratio
- 5.39
- Price to FCF
- 15.87
- Price to Operating Cash Flow
- 15.10
- PEG Ratio
- -1.37
Income Statement
In the last 12 months, Basilea Pharmaceutica had revenue of 232.40M and earned 40.20M in profits. Earnings per share was 3.29.
- Revenue
- 232.40M
- Gross Profit
- 193.10M
- Operating Income
- 51.60M
- Pretax Income
- 45.90M
- Net Income
- 40.20M
- EBITDA
- 53.41M
- Earnings Per Share (EPS)
- 3.29
Cash Flow
In the last 12 months, operating cash flow was 58.01M and capital expenditures -2.71M, giving a free cash flow of 55.30M billion.
- Operating Cash Flow
- 58.01M
- Free Cash Flow
- 55.30M
- Free Cash Flow per Share
- 4.47
Dividends & Yields
Basilea Pharmaceutica pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.30%
- Earnings Yield
- 5.98%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- 53.30%
- 50-Day Moving Average
- 66.89
- 200-Day Moving Average
- 56.81
- Relative Strength Index (RSI)
- 58.58
- Average Volume (3m)
- 13.64K
Important Dates
Basilea Pharmaceutica upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 18, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Basilea Pharmaceutica as a current ratio of 5.11, with Debt / Equity ratio of 69.73%
- Current Ratio
- 5.11
- Quick Ratio
- 4.68
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 1.12
- Interest Coverage Ratio
- 15.37
Taxes
In the past 12 months, Basilea Pharmaceutica has paid 5.60M in taxes.
- Income Tax
- 5.60M
- Effective Tax Rate
- 0.12
Enterprise Valuation
Basilea Pharmaceutica EV to EBITDA ratio is 12.34, with an EV/FCF ratio of 14.19.
- EV to Sales
- 3.17
- EV to EBITDA
- 12.34
- EV to Free Cash Flow
- 14.19
- EV to Operating Cash Flow
- 13.53
Balance Sheet
Basilea Pharmaceutica has CHF 175.98M in cash and marketable securities with CHF 83.44M in debt, giving a net cash position of CHF 92.54M billion.
- Cash & Marketable Securities
- CHF 175.98M
- Total Debt
- CHF 83.44M
- Net Cash
- CHF 92.54M
- Net Cash Per Share
- CHF 6.88
- Tangible Book Value Per Share
- CHF 13.11
Margins
Gross margin is 87.67%, with operating margin of 23.90%, and net profit margin of 21.15%.
- Gross Margin
- 87.67%
- Operating Margin
- 23.90%
- Pretax Margin
- 23.72%
- Net Profit Margin
- 21.15%
- EBITDA Margin
- 25.72%
- EBIT Margin
- 23.90%
Analyst Forecast
The average price target for Basilea Pharmaceutica is CHF 110.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 110.00
- Price Target Upside
- 55.15% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 4.74%
- EPS Growth Forecast
- -28.96%